Proteome Regulatory News (PRM)

 16 May 2025

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Annual General Meeting Statement

At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, will make the following statement:

"The recovery from the global challenges affecting the pharmaceutical and biotech markets in the second half of 2024 has continued in 2025. Following the announcement in February of the major services contract with a US pharma the pipeline of orders continues to expand now extending well into 2026 with a similar trend at our San Diego facility with eight projects ongoing. It is too early to establish whether the recent tariff changes by the US Government could affect TMT reagent revenues, but any impact is likely to be short lived. We continue to positively progress licensing discussions for our new DXT tags for multiplexing DIA which we are excited to be presenting in June at the American Society for Mass Spectrometry ("ASMS") in Baltimore. After completing our first commercial single cell proteomics ("SCP") project in January, we are discussing a follow up order with the same customer with other SCP projects ongoing. The extra capacity from the two additional mass spectrometry systems installed at our main Frankfurt site are working at full capacity to meet the increased level of orders in our services business. After considerable increases in customer orders and services, demand for our proteomics business has rebounded strongly and we are optimistic that it is well positioned to deliver substantial future increases in revenue and returns."

For further information:

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.